Morepen Laboratories: Stock jumps 4% after forming JV with UAE firmMorepen Laboratories: Stock jumps 4% after forming JV with UAE firm

Introduction

Leading pharmaceutical company’s subsidiary has entered a joint venture with UAE-based Bimedical FZE to manufacture, trade, and sell medical device products in India, with equal shareholding and indirect 30% ownership by the parent.

Also Read: Sudarshan Pharma: Stock hits upper circuit after signing agreement with Srigen Lifesciences

Share price movement of Morepen Labs

On September 9, 2025, Morepen Laboratories Ltd opened at ₹49.62, up 1.02% from its previous close of ₹49.10. The stock reached a high of ₹51.93 (5.70%) and a low of ₹49.62. By 12:20 PM, it traded at ₹50.69, a 3.24% increase, with a market cap of ₹2,777.58 crore.

Morepen Labs Forms Joint Venture in Medical Devices

Morepen Medipath Limited, a subsidiary of Morepen Laboratories Limited, has executed a joint venture agreement with Bimedical FZE, UAE, to form a new joint venture company in India focused on medical devices.

The joint venture will be equally owned, with MML and Bimedical FZE contributing 50% each to the share capital. Morepen Laboratories will indirectly hold 30% through its subsidiary, MML.

The proposed JVC will manufacture, trade, and sell medical device products. The incorporation date, name, and paid-up capital are yet to be finalized.

Recent news on Morepen Labs

As of July 23, 2025, Morepen Laboratories Ltd announced the incorporation of a new subsidiary, Morepen Medical Equipment Trading L.L.C in Dubai, focusing on international sales and marketing of medical devices. Morepen holds 60% shares.

Stock performance of Morepen Labs for Period of 1 week, 6 months, and 1 year

Morepen Laboratories Ltd delivered a 1.20% return over the past week, gained 10.0% over the past six months, and declined 47.8% over the past year.

Also Read: Brigade Enterprises: Stock jumps after signing agreement for residential development in Bengaluru

Shareholding pattern of Morepen Labs

Particulars	Jun 2025	Mar 2025	Dec 2024
Promoter	35.70%	35.70%	35.70%
FII	1.70%	1.90%	2.20%
DII	1.50%	1.70%	2%
Public	61.10%	60.70%	60.50%

About Morepen Labs

Morepen Laboratories Ltd (NSE: MOREPENLAB) manufactures and markets Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and home health products. The company focuses on production, development, and distribution across domestic and international markets.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs